Kinetics Medical Fund No Load Class

 (MUTF:MEDRX)   Watch this mutual fund  
Find more results for MUTF:MEDRX


Trailing returns

1 day   +0.76%
1 week
4 week   +1.42%
3 month   +4.27%
YTD   +4.40%
1 year   +9.76%
3 years*   +4.04%
5 years*   +13.19%
Best 3 month return+22.62%  
Worst 3 month return-24.86%  

Morningstar statistics

Morningstar category: Health
  Return Risk Rating
3 years Below Average Average
5 years Below Average Average
10 years Below Average Average
Overall Below Average Average
Morningstar style  Learn more
Value Blend Growth  

Key statistics

Total assets21.35M 
Front load-  
Deferred load-  
Expense ratio1.39%  
Management fee-  
Fund familyKinetics 

Asset allocation


Purchase information

IRA Initial$2,500  
Mar 22, 8:00PM EDT Overall Morningstar RatingTM


The investment seeks long-term growth of capital. The fund is a non-diversified fund that invests all of its investable assets in the Medical Portfolio, a series of Kinetics Portfolios Trust. The Portfolio invests at least 80% of its net assets plus any borrowings for investment purposes in common stocks, convertible securities, warrants, and other equity securities having the characteristics of common stocks of U.S. and foreign companies engaged in medical research, pharmaceutical and medical technology industries and related technology industries, with an emphasis toward companies engaged in cancer research and drug development. It is non-diversified.
Fund filings (PDF) »
Asset manager:
Bruce Abel (Started: Sep 30, 1999)
Advisor Company:
Kinetics Asset Management LLC
Fund family reports on Morningstar »
Kinetics, 615 E. Michigan Street, Milwaukee,WI53202, USA


  1 year 3 years 5 years 10 years  
Alpha* -6.43 -0.64 6.05 5.95
Beta* 0.98 0.93 0.92 0.76
Mean annual return 1.13 0.36 1.16 0.85
R-squared* 31.12 43.78 44.81 60.43
Standard deviation 14.81 15.11 15.15 16.53
Sharpe ratio 0.89 0.27 0.91 0.58
* Against standard index

Top 10 holdings

Security Net Assets  
Bristol-Myers Squibb Company (BMY) 7.63%  
Biogen Inc (BIIB) 7.60%  
Eli Lilly and Co (LLY) 6.86%  
Pfizer Inc (PFE) 6.51%  
Alkermes PLC (ALKS) 6.48%  
Johnson & Johnson (JNJ) 5.91%  
Sanofi SA ADR (SNY) 4.90%  
Albany Molecular Research Inc (AMRI) 4.90%  
Lonza Group Ltd (LZAGF) 4.84%  
Shire PLC ADR (SHPG) 4.76%